BSD Medical announced it has experienced a 391 percent increase in sales for its MicroThermX Microwave Ablation System product line for September 2012. This is in contrast with sales from September 2011. The company’s disposable SynchroWave antennas made up a substantial portion of these sales, indicating the success of BSD Medical’s fee-per-use equipment rental program and growing utilization of MicroThermX equipment.
The sales increase also represents dramatic sales growth for MicroThermX products and indicates a continuing trend of accelerating MicroThermX revenue. Sales of MicroThermX products also increased substantially during the fourth quarter of fiscal year 2012, as compared to the fourth quarter of fiscal year 2011.
A leader in providing medical systems that utilize heat therapy for treating cancer, BSD Medical introduced MicroThermX into its product line as an innovative, high-end disposable used in each ablation treatment – providing a significant ongoing revenue stream. The company’s focus for the past year has been increasing MicroThermX revenues by expanding the fee-per-use equipment rental program and direct sales support in major metropolitan areas of the United States. The company is seeing great success from these programs, and the present fiscal year promises continued growth in revenues from the MicroThermX products.
A compact, mobile, state-of-the-art proprietary system, the MicroThermX Microwave Ablation System includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The MicroThermX’s pioneering design is the first of its kind to allow delivery of higher power levels using a single generator. The innovative synchronous phased array technology utilized in the MicroThermX was developed and patented by BSD and provides larger and more uniform zones of ablation during a single procedure.
The global market for soft tissue ablation has a potential estimated at more than $2.3 billion, and the MicroThermX system promises to provide a perpetual revenue stream for BSD. The FDA has granted the company a 510(k) clearance for marketing the MicroThermX for ablation of soft tissue, and the company has additionally received CE marking for the system, which permits BSD to market the MicroThermX in Europe. CE marking is also recognized in various countries outside the E.U., opening up marketing potential of the MicroThermX to many international markets.
BSD Medical is engaged in developing, manufacturing, marketing, and servicing systems for treating cancer and benign diseases through the use of heat therapy – delivered using focused radiofrequency (RF) and microwave energy. The company’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems – used for several years in the U.S., Europe, and Asia – are used for treating certain tumors with heat (hyperthermia) while increasing other therapies’ effectiveness, including radiation therapy. The company’s microwave ablation system has been developed as a standalone therapy to ablate and destroy soft tissue. BSD has additionally developed vast intellectual property, multiple products in the market and well-established distribution in the U.S., Europe, and Asia. Some of the company’s products have received regulatory approvals in the U.S., Europe, and China.
For more information, visit the company’s Web site at www.BSDMedical.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
